fluoropyrimidine, HER2-yakanaka, oxaliplatin, Iyo kambani Seagen Inc, tucatinib, Tukysa
Mvumo yekukurumidza inopihwa neFDA kune tucatinib ine trastuzumab yegomarara remukati.
Muna Kukadzi 2023, iyo Chikafu neDrug Administration (FDA) yakawedzera kubvumidzwa kwetucatinib (Tukysa, Seagen Inc.) uye trastuzumab kurapwa kweRAS yemusango-mhando HER2-positive colorectal cancer iyo yapararira kana isingakwanise kudzoreredzwa.
Adcetris, brentuximab vedotin, Hodgkin lymphoma yekare, Iyo kambani Seagen Inc
Brentuximab vedotin inotenderwa neFDA pamwe chete nechemotherapy yevana varwere vane classical Hodgkin lymphoma.
Mbudzi 2022: Iko kusanganiswa kwe doxorubicin, vincristine, etoposide, prednisone, uye cyclophosphamide ine brentuximab vedotin (Adcetris, Seagen, Inc.) yakabvumidzwa neFood and Drug Administration kuti ishandiswe muvana.